Latest Proton pump inhibitors Stories
On December 6th, 2012, 39 lawsuits alleging Nexium caused bone fractures were consolidated in the Multidistrict Litigation MDL 2404 (Central District of California) by the U.S. Judicial Panel. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of alleged Nexium severe adverse events. [http://www.attorneyone.com/nexium-lawsuits/...
BOCA RATON, Fla., Dec. 18, 2012 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Prescription Lansoprazole Delayed-Release Capsules. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA), which is being manufactured and supplied by Natco Pharma Limited, and will be available in both 15mg and 30mg strengths. Lansoprazole Delayed-Release Rx Capsules are AB rated to Prevacid®, a Proton Pump...
WOODCLIFF LAKE, N.J., Dec. 11, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) determined that Eisai has met the FDA's Written Request requirements for pediatric exclusivity for ACIPHEX(® )(rabreprazole sodium). As a result, Eisai has now gained an additional 6 months of United States market exclusivity for ACIPHEX, which will expire on November 8, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The granting of...
WOODCLIFF LAKE, N.J., Nov. 30, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex® Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age. (Logo:...
PARSIPPANY, N.J. and MUMBAI, India, Sept. 17, 2012 /PRNewswire/ -- Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 15mg and 30 mg delayed release capsules of Lansoprazole, which is used in treatment of peptic ulcers. Lansoprazole is the generic name for the brand Prevacid(®), marketed in the United States by Takeda. Wockhardt is launching the product immediately. (Logo:...
New research study “Gastric Cancer - Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020” prepared by GlobalData has been recently published by Market Publishers Ltd. The report finds that the global gastric cancer drug market will experience robust growth over the next decade. London, UK (PRWEB) September 04, 2012 The global gastric cancer drug market will experience robust growth over the next decade, driven by the rapid uptake and market expansion...
Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or MetronidazoleTokyo/Osaka, Aug 31, 2012 - (JCN Newswire) - Takeda Pharmaceutical Company Limited (Headquarters: Osaka, President: Yasuchika Hasegawa), AstraZeneca K.K. (Headquarters: Osaka, President: Paul Hudson), Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka; President: Michihiro Tsuchiya), and Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito)...
The findings of the study published in July 2012 on The American Journal of Gastroenterology, revealed a 65% increase in the incidence of clostridium difficile-associated diarrhea (CDAD) among users of PPIs (Proton Pump Inhibitors), including Nexium. Nexium, manufactured by AstraZeneca, is a medication that people take to prevent on-going heartburn. In February 2012, the US FDA issued a drug safety communication notifying the public that the use of stomach acid drugs known as proton pump...
THE WOODLANDS, Texas, July 10, 2012 /PRNewswire/ -- Pernix Therapeutics (NYSE: MKT: PTX), a specialty pharmaceutical company, today announced that Omeclamox-Pak(®) is now available to patients for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients. Omeclamox-Pak is a ten-day, triple combination oral therapy comprised of omeprazole delayed-release capsules (20 mg),...
In April 2012, MHRA published an article revealing that there is recent epidemiological evidence of an increased risk of fracture with long-term use of PPIs (Proton Pump Inhibitors), including Nexium. Nexium, manufactured by AstraZeneca, is a medication that people take to prevent on-going heartburn. According to court documents, on April 19th, 2011, an Ohio woman, Ginny Begin, filed a lawsuit Texas Southern District Court (case no. 4:2011cv01489) against AstraZeneca, alleging that she...
